Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Three Times Weekly Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis
Ann Neurol 73:705-713, Khan, O.,et al, 2013
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
NEJM 367:1087-1097,1149, Fox, R.J.,et al, 2012
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Ann Neurol 69:75-82, Comi,G.,et al, 2011
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Efficacy of Treatment of MS with IFN B-1b or Glatiramer Acetate by Monthly Brain MRI in the BECOME Study
Neurol 72:1976-1983,1972, Cadavid,D.,et al, 2009
The Present Efficacy of Multiple Sclerosis Therapeutics
Neurol 73:984-990, Klawiter,E.,et al, 2009
Effect of Glatiramer Acetate on Conversion to Clinically Definite Multiple Sclerosis in Patients with Clinically Isolated Syndrome (PreCISe study): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 374:1503-1511, 1475, Martinelli,G.,et al, 2009
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Glatiramer Acetate--Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma
Arch Neurol 65:1378-1379, Madray,M.M.,et al, 2008
Randomized, Double-Blind, Dose-Comparison Study of Glatiramer Acetate in Relapsing-Remitting MS
Neurol 68:939-944, Cohen,J.A.,et a, 2007
Severe Anaphylactic Reaction to Glatiramer Acetate with Specific IgE
Neurol 64:1481-1482, Rauschka,H.,et al, 2005
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Copaxone's Effect on MRI-Monitored Disease in Relapsing MS is Reproducible and Sustained
Neurol 59:1284-1286, Wolinsky,J.S.,et al, 2002
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetate on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients wi
Ann Neurol 49:290-297, Comi,G.,et al, 2001
Glatiramer Acetate (Copaxone) Treatment in Relapsing-Remitting MS
Neurol 54:813-817, Ge,Y.,et al, 2000
Multiple Sclerosis,Therapeutic Update
Arch Neurol 56:277-280, Tselis,A.C.&Lisak,R.P., 1999
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Neuropsychological Status in Multiple Sclerosis after Treatment with Glatiramer
Arch Neurol 56:319-324, Weinstein,A.,et al, 1999
Effects of Copolymer-1 on Serial Gadolinium-Enhanced MRI in Relapsing Remitting Multiple Sclerosis
Neurol 50:1127-1133, Mancardi,G.L.,et al, 1998
Extended Use of Glatiramer Acetate (Copaxone) Is Well Tol & Maint Its Clin Effect on MS Relapse Rate & Degree of Disabil
Neurol 50:701-708, Johnson,K.P.,et al, 1998
Current Immunotherapy in Multiple Sclerosis
Immunology and Cell Biology 76:55-64, Bashir,K.&Whitaker,J.N., 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Glatiramer Acetate for Relapsing Multiple Sclerosis
The Medical Letter 39:61-62, , 1997
Copolymer 1 Reduces Relapse Rate & Improves Disability in Relapsing-Remitting MS:Multictr Trial
Neurol 45:1268-1276, Johnson,K.P.,et al, 1995
A Placebo-Controlled, Double-Blind, Randomized, Two-Center, Pilot Trial of Cop 1 in Chronic Progressive MS
Neurol 41:533-539, Bornstein,M.B.,et al, 1991
Immunotherapy of Multiple Sclerosis
Ann Neurol 23:211-223, Weiner,H.L.&Hafler,D.A., 1988
A Pilot Trial of Cop 1 in Exacerbating-Remitting Multiple Sclerosis
NEJM 317:408-414, 442-4441987., Bornstein,M.B.,et al, 1987
Fluorodeoxyglucose PET/CT as Possible Early Diagnostic Tool Preceding MRI Changes in Borna Disease Virus 1 Encephalitis
Lancet 403:665-666, Bayas, A., et al, 2024
Magnetic Resonance Imaging Characteristics of LGl1-Antibody and CASPR2-Antibody Encephalitis
JAMA Neurol 81:525-533, Kelly,Mark J., et al, 2024
Leptomeningitis with Communicating Hydrocephalus in an Immunocompromised Patient with Disseminated Sporotrichosis
Neurol 103:e209586, Taborda,M.H.,et al, 2024
MR Imaging Findings in Anti-Leucine-Rich Glioma Inactivated Protein 1 Encephalitis:A Systematic Review and Meta-Analysis
AJNR 45:977-986, Almeida,F.C.,et al, 2024
An Unusual Etiology of Lumbosacral Plexopathy in a Patient with HIV
Neurol 103:e209930, Madduluri,B.,et al, 2024
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
NEJM 391:1193-1205, Malhotra,A.,et al, 2024
Rapidly Progressive Dementia in a Man With HIV Infection and Undetectable Plasma Viral Load
Neurol 100:344-348, Chishimba,L.C.,et al, 2023
Progressive Hemiparesis and White Matter Abnormalities in an HIV-Negative Patient
Neurol 100:1156-1163, Jabbari,E.,et al, 2023
Glucose Hypermetabolism in the Basal Ganglia
Neurol 101:90-91, Kim,Y.E.,et al, 2023
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma
Neurol 101:e2472-e2482, Pepys,J.,et al, 2023
Confused About Confusion
NEJM 386:80-87, Spanjaart, A.M.,et al, 2022
Efficacy and Safety of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1
Neurol 98:e938-e946, Hwang, J.,et al, 2022
Toward Simpler, Safer Treatment of Cryptococcal Meningitis
NEJM 386:1179-1181, Moosa, M.Y.S. & Lessells, R.J., 2022
A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022
In Patients with Melanoma Brain Metastases, is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic
Neurologist 27:290-297, Gritsch, D.,et al, 2022
New Onset Focal Tremor in Patient with Human Immunodeficienccy Virus
Clin Infect Dis 75:1861-1863, Finelli,P.F., 2022
Spinal Muscular Atrophy
UpToDate, Oct, Bodamer,O.A., 2022
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021